NDC 0409-1276-03 - Fentanyl Citrate
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0409-1276
- Requested NDC
- 0409-1276-03
- Package NDCs from labels
- 0409-1276-03, 0409-1276-32
- Manufacturer
- Hospira, Inc.
- Effective date
- 2023-10-26
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Fentanyl Citrate - Hospira, Inc. | Hospira, Inc. | 2023-10-26 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0409-1276-03 | ML - Milliliter | 0409-1276 | 588b4102-863e-4342-b69f-068c9e89ff9c | 1 | 2016-12-07 |
| 0409-1276-32 | ML - Milliliter | 0409-1276 | 9fe4e503-e46c-4787-a9b9-983d7b06f203 | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| FENTANYL CITRATE | ACTIVE INGREDIENT | MUN5LYG46H | FENTANYL CITRATE INJECTION, SOLUTION [HOSPIRA, INC.] | 16 | |
| FENTANYL | ACTIVE MOIETY | UF599785JZ | FENTANYL CITRATE INJECTION, SOLUTION [HOSPIRA, INC.] | 16 | |
| SODIUM HYDROXIDE | INACTIVE INGREDIENT | 55X04QC32I | FENTANYL CITRATE INJECTION, SOLUTION [HOSPIRA, INC.] | 16 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Fentanyl Citrate | FENTANYL CITRATE | Hikma Pharmaceuticals USA Inc. | ce5db1c2-feb1-4ad2-847a-d02e865bd47e | 2026-10-23 | Boxed warning, Warnings, Adverse reactions | MUN5LYG46H |
| Fentanyl Citrate | FENTANYL CITRATE | Phlow Corp. | 58dcd3f7-e3d8-4929-a186-8f680a51ff11 | 2026-10-23 | Boxed warning, Warnings, Adverse reactions | MUN5LYG46H |
| Fentanyl Citrate | FENTANYL CITRATE | Hospira, Inc. | bfa8018a-4cbc-434b-e09e-782872b0340a | 2026-08-24 | Boxed warning, Warnings, Adverse reactions | MUN5LYG46H |
| FENTANYL CITRATE | FENTANYL CITRATE | Hospira, Inc. | 1ed25b2c-334e-4021-ada1-3396f07630dc | 2026-04-07 | Boxed warning, Warnings, Adverse reactions | MUN5LYG46H |
| Fentanyl Citrate | FENTANYL CITRATE | Civica, Inc. | aacf276b-e133-4199-ad3f-67b894744c04 | 2025-12-26 | Boxed warning, Warnings, Adverse reactions | MUN5LYG46H |
| Fentanyl Citrate | FENTANYL CITRATE | Hikma Pharmaceuticals USA Inc. | c5fcdcbd-1dd1-4ebf-aa0d-edfe845414b7 | 2025-12-19 | Boxed warning, Warnings, Adverse reactions | MUN5LYG46H |
| Fentanyl Citrate | FENTANYL CITRATE | Fresenius Kabi USA, LLC | 0c10e465-4117-48ba-a454-23ccb7a3fcc7 | 2025-09-24 | Boxed warning, Warnings, Adverse reactions | MUN5LYG46H |
| Fentanyl Citrate | FENTANYL CITRATE | Fresenius Kabi USA, LLC | 38d0c14a-a0c1-44cc-a939-0304eb8037d6 | 2024-12-31 | Boxed warning, Warnings, Adverse reactions | MUN5LYG46H |
| 3989ffa0-90a2-4311-a449-97c3ac697244 | a13ae145-5c5e-422b-d0a5-6cf34c1b8262 | 2024-07-26 | Boxed warning, Warnings, Adverse reactions | a13ae145-5c5e-422b-d0a5-6cf34c1b8262 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.